SEC Form 4 · accession 0000882104-15-000010
PDL BIOPHARMA, INC. · PDLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Lewis Stone
Officer — VP, Gen. Counsel & Secretary
Period of report
Jan 28, 2015
Accepted (ET)
Jan 30, 2015 · 4:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882104
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1 | Jan 28, 2015 | A | 33,110 | $7.62 | A | 140,473 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The restricted stock will vest, provided that the officer remains employed by the Company and certain performance goals are achieved, based upon the following schedule: 50% on December 2016; 16.66% on January 2017; 16.66% on January 2018; and 16.66% on January 2019.